$CATX

Lantheus Alpha Therapy, LLC sold $777K of CATX

Lantheus Alpha Therapy, LLC sold 247,932 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.13 ($3.11–$3.15, $0.78M total) across 2 trades over 2026-09-03 to 2026-09-04. Filed jointly with Lantheus Holdings, Inc. (10% owner).

Original reporting
SEC EDGAR · Lantheus Alpha Therapy, LLC, Lantheus Holdings, Inc.
Published Sep 8, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CATX
Neutral
high confidence
Mentioned
$CATX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CATXNeutralLow
01

Why it matters

The transaction represents a modest reduction in stake by a major owner, with limited immediate market effect.

02

Market read

Low relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data that prompted the sale.

Relevance 5/10Novelty 3/10Timing: filing today

Background

Form 4 filing by Lantheus Alpha Therapy, LLC reporting a sale of Perspective Therapeutics shares.

Company-level read

Ticker impact

$CATXNeutralHigh confidence
Context

SEC Form 4 disclosed a $777K open‑market sale of 247,932 shares by a 10% owner.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

Sale size is small relative to market cap and ownership remains high.

Market effects

No broader sector impact; isolated insider transaction.

None

None

Counterpoint

Insider may be reallocating capital; could signal confidence in future upside.

Key entities

  • Perspective Therapeutics, Inc.

    Biopharma issuer of CATX.

  • Lantheus Alpha Therapy, LLC

    Reporting insider holder.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CATXMed

Perspective Therapeutics, Inc. (CATX): Results of Operations and Financial Condition

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 s